{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
m nalidixic acid
to a specific field?
Status:
Investigational
Source:
NCT04566679: Not Applicable Interventional Unknown status Irritable Bowel Syndrome (IBS)
(2021)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
INN:stibosamine [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Stibosamine is a Salts of p-aminophenylstibinic acid and N-ethylethanamine patented by Hynson, Westcott & Dunning for the treatment kala-azar infection.
Status:
Class (Stereo):
CHEMICAL (EPIMERIC)
Detajmium bitartrate anhydrous is Rauwolfia alkaloid. It is a sodium-channel-blocking drug with an extremely long recovery from use-dependent sodium channel block. Detajmium has antiarrhythmic properties. It caused comparable prolongations of the intraventricular conduction time during sinus rhythm and progressively broadened the QRS complex. Rauwolfia alkaloids use is restricted by serious adverse effects, such as dysrhytmias. Several detajmium bitartrate lethal intoxications were reported.
Class (Stereo):
CHEMICAL (RACEMIC)
Phenobutiodil was used as the contrast medium in radiology. As a diagnostic aid in cholecystography. Conjugated phenobutiodil (Biliodyl) in the small and large bowel can be recognized by its fine, homogeneous appearance.
Status:
Investigational
Source:
NCT00129194: Phase 1 Interventional Completed HIV Infections
(2005)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
KP-1461 is a prodrug of KP-1212, an antiviral agent developed for the treatment of human immunodeficiency virus (HIV) infection. KP-1212 induces an increase in the HIV mutation rate thus leading to viral ablation.
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
Orpanoxin (previously known as F-776), a nonsteroidal anti-inflammatory drug that was developed as an analgesic agent. Orpanoxin is a prostaglandin synthetase inhibitor and may have a potential for the treatment of rheumatic. However, information about the current development of this drug is not available.
Class (Stereo):
CHEMICAL (RACEMIC)
Prodolic acid is an indole derivative patented by American Home Products Corp. as antiinflammatory agent. Prodolic acid acts as non-steroidal anti-inflammatory compound and inhibits bradykinin-induced bronchoconstriction but did not affects histamine-induced bronchoconstriction in the guinea pig. In preclinical studies, Prodolic acid exhibits potent anti-inflammatory activity in adjuvant arthritic rats.
Class (Stereo):
CHEMICAL (ACHIRAL)
Nibroxane, 5-bromo-2-methyl-5-nitro-m-dioxane, is a topically effective antimicrobial agent with a broad spectrum of activity. Nibroxane is unusual in that it not only possesses high microbiocidal activity against Gram positive (Staphylococcus uureus) and Gram negative (Pseudomonas aeruginosa) bacteria
but also against yeasts (Candida albicans) and moulds (Aspergillus niger). In addition, the 5-bromo-5-nitro-m-dioxanes have, as a class of compounds, the distinct advantage of being chemically stable over a wide pH range. This inherent stability,
coupled with its broad spectrum of microbiocidal activity, makes nibroxane an excellent candidate as a preservative for cosmetic and pharmaceutical formulations.
Status:
Investigational
Source:
NCT03594058: Phase 2 Interventional Completed Overactive Bladder
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Solabegron (GW427353), a beta-3 adrenoceptor agonist, is in development with AltheRx (now Velicept Therapeutics) for the treatment of irritable bowel syndrome (IBS) and overactive bladder (OAB). Solabegron was discovered and first developed by GlaxoSmithKline. It was acquired by AltheRx, which merged with Velicept in 2015 to continue development of the program. Solabegron has been tested in over 800 study subjects in a twice-a-day formulation and demonstrated efficacy in the treatment of OAB as well as IBS. A once daily formulation designed to optimize patient convenience as well as efficacy has been developed and is currently being evaluated in a phase 2b dose ranging clinical trial. A Phase 2b dose ranging study with the twice daily formulation also began enrollment in Q1 2018.
Status:
Class (Stereo):
CHEMICAL (RACEMIC)
